Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2. Ann Oncol. 2016. PMID: 27484801 Free article. Clinical Trial.
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P. Guarneri V, et al. Among authors: ficarra g. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590635 Free article. Clinical Trial.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Guarneri V, et al. Among authors: ficarra g. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. Oncologist. 2015. PMID: 26245675 Free PMC article. Clinical Trial.
Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Breast Cancer Res. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. Breast Cancer Res. 2018. PMID: 29929548 Free PMC article.
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Among authors: ficarra g. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Breast Cancer Res Treat. 2017. PMID: 28289852
203 results